Ormeloxifene
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
 |
This article or section is in need of attention from an expert on the subject. WikiProject Medicine or the Medicine Portal may be able to help recruit one. |
| Ormeloxifene
| |
| Background | |
| B.C. type | Anti-estrogen |
| First use | 1988 |
| Failure rates (first year) | |
| Perfect use | 2% |
| Typical use | 9% |
| Usage | |
| Duration effect | One week |
| Reversibility | Immediate |
| User reminders | Taken twice weekly for first 13 weeks |
| Clinic review | Annually |
| Advantages and Disadvantages | |
| STD protection | No |
| Periods | May disrupt |
| Weight | No proven effect |
| Medical notes | |
| Only approved as a contraceptive in India | |
| Image:Ormeloxifene.svg | |
| Ormeloxifene
| |
| Systematic (IUPAC) name | |
| 1-[2-[4-[(3S,4R)-7-methoxy-2,2- dimethyl-3-phenyl-chroman-4-yl] phenoxy] ethyl] pyrrolidine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C30H35NO3 |
| Mol. mass | 457.604 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 7 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Ormeloxifene (also known as Centchroman) is one of the selective estrogen receptor modulators, or SERMs, a class of medication which acts on the estrogen receptor. It is best known as a non-hormonal, non-steroidal oral contraceptive which is taken once per week. In India, ormeloxifene has been available as birth control since the early 1990s, and it is currently marketed there under the trade name Saheli. Ormeloxifene has also been licensed under the trade names Centron and Sevista.
Method of action
Ormeloxifene is a SERM, or selective estrogen receptor modulator. In some parts of the body, its action is estrogenic (e.g, bones), in other parts of the body, its action is anti-estrogenic (e.g., uterus, breasts).[citation needed] It causes an asynchrony in the menstrual cycle between ovulation and the development of the uterine lining, although its exact mode of action is not well defined. In clinical trials, it caused ovulation to occur later than it normally would in some women (Singh 2001), but did not affect ovulation in the majority of women, while causing the lining of the uterus to build more slowly. It speeds the transport of any fertilized egg through the fallopian tubes more quickly than is normal (Singh 2001). Presumably, this combination of effects creates an environment such that if fertilization occurs, implantation will not be possible.[1]
Usage
Ormeloxifene may be used as a contraceptive or as a treatment for dysfunctional uterine bleeding.
As birth control
Ormeloxifene may be used as a weekly oral contraceptive. This is touted as a major advantage by its developer and its manufacturer. Hormonal birth control pills should be taken at approximately the same time each day. In the case of progestogen only pills other than Cerazette that do not consistently inhibit ovulation, a delay of as little as three hours can increase the risk of pregnancy because of the limited duration of their effect on the cervical mucus. Ormeloxifene's weekly schedule is an advantage for women who prefer an oral contraceptive, but find it difficult or impractical to adhere to a daily schedule.
For the first twelve weeks of use, it is advised to take the ormeloxifene pill twice per week. From the thirteenth week on, it is taken once per week. The consensus is that backup protection in the first month is a cautious but sensible choice.[citation needed]
Effectiveness
One Phase III multicenter trial of ormeloxifene 30 mg weekly by 898 women for an average of 15 months found a method failure Pearl Index of 2.84.[1]
A second Phase III multicenter trial of ormeloxifene 30 mg twice-a-week for 3 months followed by 30 mg weekly by 376 women for an average of 10.5 months found a method failure Pearl Index of 1.83 and a 12-month life-table method failure pregnancy rate of 1.63% ±0.74%.[1]
The overall actual use (method failure plus user failure) Pearl Index was 9 in both Phase III multicenter trials of ormeloxifene — an order of magnitude less effective than found in Phase III multicenter trials of combined oral contraceptive pills.[1]
Manufacture and marketing
Ormeloxifene has been tested and licensed as a form of birth control, as well as a treatment for dysfunctional uterine bleeding. It was first manufactured by Torrent Pharmaceuticals, and marketed as birth control under the trade name Centron. Centron was discontinued. A new license for ormeloxifene was issued to Hindustan Latex Ltd., which now manufactures ormeloxifene as birth control under the trade name Saheli. Torrent Pharmaceuticals has resumed manufacture of ormeloxifene under the trade name Sevista, as a treatment for dysfunctional uterine bleeding.
See also
References
External links
- United States National Library of Medicine Ormeloxifene entry in the Medical Subject Headings (MeSH) database
- United States National Library of Medicine Centchroman entry in the Medical Subject Headings (MeSH) database
- Reproductive Health Online, a Johns Hopkins University affiliate providing information on Centchroman
- Saheli manufacturer's website - Product details
- Saheli manufacturer's website - Clinical studies
- Central Drug Research Institute, Lucknow, India: a government-funded laboratory, conducting R&D on Centchroman as birth control.
- Ministry of Health and Family Welfare - Indian government site; information about availability of Saheli.
- Aphrodite Women's Health - user experiences of Centchroman
- Centchroman Health Group - user experiences of Centchroman
Birth control | |
|---|---|
| Comparison: | Comparison of birth control methods |
| Behavioral: | Avoiding vaginal intercourse: Anal sex, Oral sex, Non-penetrative sex, Masturbation, Abstinence Including vaginal intercourse: Fertility awareness, Rhythm Method, Withdrawal, Breastfeeding infertility |
| Barrier: | Condom, Female condom, Diaphragm, Cervical cap, Lea's Shield |
| Spermicide: | Contraceptive sponge |
| Hormonal: | Combined: Combined oral contraceptive pill ('the Pill'), Contraceptive patch, NuvaRing, Combined injectable contraceptive Progestogen only: Progestogen only pill ('minipill'), Depo-Provera, Norplant/Jadelle, Implanon |
| Anti-estrogen: | Ormeloxifene (a.k.a. Centchroman) |
| Intra-uterine: | IUD (copper or progestogen), IUS (progestogen) |
| Post-intercourse: | Contraception: Emergency contraception (pills or copper IUD) Abortion: Surgical abortion, Medical abortion (RU-486/abortion pill) |
| Sterilization: | Male: Vasectomy Female: Tubal ligation, Essure |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
